Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir.

The Journal of antimicrobial chemotherapy - 15 Jul 2021

Brenner Bluma G, Oliveira Maureen, Ibanescu Ruxandra-Ilinca, Routy Jean-Pierre, Thomas Réjean

Abstract excerpt

BACKGROUND: The newer generation NNRTIs, including doravirine and rilpivirine, were designed to show high potency and overcome K103N, Y181C and G190A resistance. OBJECTIVES: To assess emergent resistance to doravirine and rilpivirine, alone and paired with lamivudine or islatravir through in vitro drug selections. METHODS: Subtype B (n = 3), non-B subtype (n = 3), and pNL4.3 viral isolates were passaged in cord...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Cell Culture Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxyadenosines

Share to Drug Resistance, Viral

Share to HIV Reverse Transcriptase

Share to Pyridones

Share to Reverse Transcriptase Inhibitors

Share to Triazoles

Source

Identifiers

PMID: 33855437
DOI: 10.1093/jac/dkab126

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir.PMID 33855437Read ↗

Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.Semantic proximity Read ↗

Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.Semantic proximity Read ↗

Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).Semantic proximity Read ↗

Variable antiviral activity of islatravir against M184I/V mutant HIV-1 selected during antiretroviral therapy.Semantic proximity Read ↗

No antagonism or cross-resistance and a high barrier to the emergence of resistance in vitro for the combination of islatravir and lenacapavir.Semantic proximity Read ↗

In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.Semantic proximity Read ↗

Kinetic Insights into the Enhanced Antiviral Activity of Islatravir against Doravirine Resistance-Associated Substitution Mutations in HIV-1 Reverse Transcriptase.Semantic proximity Read ↗

Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir.Semantic proximity Read ↗

HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes.Semantic proximity Read ↗

HIV-1 resistance to islatravir/tenofovir combination therapy in wild-type or NRTI resistant strains of diverse HIV-1 subtypesSemantic proximity Read ↗

Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro.Semantic proximity Read ↗

In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.